Current Report Filing (8-k)
20 March 2014 - 3:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
March 13, 2014
Date of Report
(Date of earliest event reported)
CANCER CAPITAL CORPORATION
(Exact name of registrant as specified in its
charter)
Nevada
(State or other jurisdiction
of incorporation) |
000-32363
(Commission File Number) |
91-1803648
(IRS Employer
Identification No.) |
2157 S. Lincoln Street, Suite 200, Salt Lake
City, Utah 84106
(Address of principal executive offices)
(801) 323-2395
(Registrant’s telephone number, including
area code)
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act
(17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act
(17 CFR 240.13e-4(c))
Section 4 - Matters Related to
Accountants and Financial Statements
Item 4.01 Changes in Registrant’s Certifying
Accountant
On March 13, 2014, Cancer Capital Corporation (the “Company”)
was informed by our independent registered public accounting firm, Morrill & Associates, LLC, ("Morrill"), that Morrill
had combined its public audit practice with Pritchett Siler & Hardy, P.C. (“Pritchett Siler”), effective March
10, 2014. As a result, Morrill effectively resigned as the Company's independent registered public accounting firm and Pritchett
Siler became the Company's independent registered public accounting firm. The engagement of Pritchett Siler as the Company's independent
registered public accounting firm was approved by our Board of Directors on March 13, 2014.
Morrill’s reports on the financial statements of
the Company as of and for the two years ended December 31, 2012 and December 31, 2011 did not contain any adverse opinion or disclaimer
of opinion and were not qualified or modified as to audit scope or accounting principles. However, Morrill’s reports
on the financial statements of the Company for the years ended December 31, 2012 and 2011 and any subsequent interim period preceding
the date of dismissal contained an explanatory paragraph disclosing the uncertainty regarding the Company’s ability to continue
as a going concern.
During the two years ended December 31, 2012 and December
31, 2011 and any subsequent interim period preceding the date of dismissal, there were no disagreements between the Company and
Morrill on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which
if not resolved to Morrill’s satisfaction would have caused it to make reference thereto in connection with its reports on
the financial statements for such periods. During the two years ended December 31, 2012 and December 31, 2011 and through the date
of this Form 8-K, there were no reportable events of the type described in Item 304(a)(1)(v) of Regulation S-K.
During the two years ended December 31, 2012 and December
31, 2011 and any subsequent interim period preceding the date of engagement, the Company (or someone on our behalf) did not consult
with Pritchett Siler with respect to (i) the application of accounting principles to a specified transaction, either completed
or proposed; (ii) the type of audit opinion that might be rendered on the Company's financial statements, and neither a written
report was provided to us nor oral advice was provided that Pritchett Siler concluded was an important factor considered by the
Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (iii) any matter that was either
the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K) or an event of the type described in Item 304(a)(1)(v)
of Regulation S-K.
The Company provided Morrill with a copy of this Current Report
on Form 8-K and requested Morrill to furnish the Company with a letter addressed to the Securities and Exchange Commission stating
whether it agrees with the statements made therein. A copy of such letter, dated March 14, 2014 furnished by Morrill, is filed
as Exhibit 16.1 to this Current Report.
Section 9 – Financial Statements and
Exhibits
Item 9.01 Financial Statements and Exhibits
Exhibit
No. |
Description |
16.1 |
Letter of agreement from Morrill & Associates, LLC, dated March 14, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 19, 2014 |
|
CANCER CAPITAL CORPORATION |
|
|
|
|
|
By: /s/ John W. Peters |
|
|
John W. Peters, President |
Cancer Capital (PK) (USOTC:CNCL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cancer Capital (PK) (USOTC:CNCL)
Historical Stock Chart
From Jul 2023 to Jul 2024